Tarsus Pharmaceuticals (TARS) Gains from Investment Securities (2019 - 2026)
Tarsus Pharmaceuticals (TARS) recorded quarterly Gains from Investment Securities of $1.9 million in Q1 2026, up 407.61% quarter-over-quarter from $381000.0 in Q4 2025.
Tarsus Pharmaceuticals (TARS) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Gains from Investment Securities history runs 8 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities changed N/A year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $2.5 million (up 402.24% YoY), while the FY2025 annual figure was $527000.0, up 37.24% from the prior year.
- Gains from Investment Securities was $1.9 million for Q1 2026 at Tarsus Pharmaceuticals, up from $381000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $1.9 million in Q1 2026 to a low of -$483000.0 in Q2 2024.
- Historically, Gains from Investment Securities has averaged $433083.3 across 5 years, with a median of $377000.0 in 2025.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities soared 1886.67% in 2023, then slumped 223.85% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$75000.0 in 2022, then jumped by 1886.67% to $1.3 million in 2023, then dropped by 27.39% to $973000.0 in 2024, then plunged by 60.84% to $381000.0 in 2025, then soared by 407.61% to $1.9 million in 2026.
- The last three Gains from Investment Securities figures came in at $1.9 million (Q1 2026), $381000.0 (Q4 2025), and $373000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Tarsus Pharmaceuticals | 2.71 Bn | 2.61 Bn | 152.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.93 Mn |
| Mar 31, 2026 | 1.93 Mn |
| Dec 31, 2025 | 381,000.00 |
| Dec 31, 2025 | 381,000.00 |
| Sep 30, 2025 | 373,000.00 |
| Sep 30, 2025 | 373,000.00 |
| Jun 30, 2025 | -227,000.00 |
| Jun 30, 2025 | -227,000.00 |
| Sep 30, 2024 | 973,000.00 |
| Sep 30, 2024 | 973,000.00 |
| Jun 30, 2024 | -483,000.00 |
| Jun 30, 2024 | -483,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Sep 30, 2023 | 1.34 Mn |
| Sep 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | 390,000.00 |
| Jun 30, 2023 | 390,000.00 |
| Mar 31, 2023 | 116,000.00 |
| Mar 31, 2023 | 116,000.00 |